Influence on study outcomes of an inpatient study by the behavior of the study staff (PINgPOng): study protocol for a randomized clinical trial연구 직원의 행동이 입원 환자 연구의 연구 결과에 미치는 영향(PINGPOng): 무작위 임상 시험을 위한 연구 프로토콜Article Published on 2022-06-132022-09-11 Journal: Trials [Category] COVID19(2023년), SARS, 임상, [키워드] administration Affect Alpha amylase analgesic Analgesic therapy analyzed Anxiety Behavior characteristic classical clinical clinical development clinical study clinical trial cold pressor test conducted cortisol covariate covariates cross-over Declaration of Helsinki Depression double-blind Drug efficacy Effect Effects Factor fixed healthy volunteer help Helsinki ICH-GCP influence intensity Neutral Oxycodone Pain pain intensity pharmacological phase Placebo Placebo effect Placebo response placebo-controlled study pressor test primary endpoint question Randomized randomized clinical trial RCT RCTs reaction response responses salivary single-center specific effect specific effects Stress study outcome Study protocol Study team. Symptom tested treated Treatment university [DOI] 10.1186/s13063-022-06436-0 PMC 바로가기 [Article Type] Article
Chapter One: Current innovative engineered antibodiesBook chapter Published on 2022-05-312022-10-05 Journal: International Review of Cell and Molecular Biology [Category] 비임상, [키워드] adverse effects antibodies antibody antibody engineering Antibody formats approval approved Autoimmune Cancer clinical development current Diseases drugs generate growth human antibodies illnesses Inflammatory diseases Mechanisms of action metabolic disease New reduced regulatory authority specificity Stage therapeutic agent therapeutic antibodies [DOI] 10.1016/bs.ircmb.2022.03.007 [Article Type] Book chapter
The Current Landscape of mRNA Vaccines Against Viruses and Cancer-A Mini Review바이러스 및 암에 대한 mRNA 백신의 현재 상황-A 미니 리뷰Review Published on 2022-05-062022-09-11 Journal: Frontiers in Immunology [Category] 유전자 메커니즘, [키워드] Against Cancer cancer vaccination cancers cause clinical development clinical trial clinical trials clinical trials of mRNA vaccines COVID-19 pandemic current death example flexible landscape limitation MINI molecular mechanisms mRNA mRNA modifications mRNA vaccine mRNA vaccine delivery mRNA vaccine developers mRNA vaccine mechanism mRNA vaccines mRNA-based multiple antigen multiple antigens Patient Personalized medicine platform Research review therapy Treatment vaccination vaccine platform viral disease viral infection viral infections viral vaccination. viruses [DOI] 10.3389/fimmu.2022.885371 PMC 바로가기 [Article Type] Review
Mass Spectrometric Assays Reveal Discrepancies in Inhibition Profiles for the SARS-CoV-2 Papain-Like Protease질량 분석 분석은 SARS-CoV-2 파파인 유사 프로테아제에 대한 억제 프로필의 불일치를 보여줍니다Article Published on 2022-05-042022-09-11 Journal: ChemMedChem [Category] COVID19(2023년), SARS, 치료제, [키워드] applied assays auranofin clinical development cysteine functional highlighting in vitro inhibit inhibition inhibitor inhibitors M pro mass mass spectrometry mechanisms MONITOR MPro Nirmatrelvir non-structural proteins Nucleophilic cysteine protease Papain Papain-like protease PF-07321332 PF-07321332/nirmatrelvir PLPro profile protease protease inhibition Proteases reported SARS-CoV-2 SARS-CoV-2 main protease SARS-CoV-2 main protease/Mpro SARS-CoV-2 papain-like protease/PLpro selected selective targets the SARS-CoV-2 utility viral protease inhibition. viral replication [DOI] 10.1002/cmdc.202200016 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study건강한 성인에서 AS03 보조제 SARS-CoV-2 재조합 단백질 백신(CoV2 preS dTM)의 안전성 및 면역원성: 2상, 무작위, 용량 찾기, 다기관 연구의 중간 결과Clinical Trial Published on 2022-05-012022-09-11 Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, [키워드] 95% CI abstinence adjuvants Adults adverse event adverse events Adverse reaction Adverse reactions age All participant All participants antibody Antibody titre Antigen AS03 assessments assigned authority baseline booster vaccination candidate vaccine Chemotherapy childbearing potential clinical development Clinical research clinical trial Cohort Contraception COVID-19 vaccine D614G variant development dose effective Endpoint enrolled evaluated expected fixed Frequency geometric mean geometric mean titre GMT GMT ratio GMTs groups healthy High dose High-dose high-dose group Immunocompromised immunogenicity increase in increased risk injection injection site Injections intensity interim results investigator investigators involved Laboratory lactating low dose low-dose medical condition Medical conditions medium medium dose Mild mild to moderate moderate multicentre Neutralising Antibodies neutralising antibody neutralising antibody titre neutralising antibody titres occurred Older Older adults Organ transplant outcome outcome assessor outcome assessors parallel-group participant Participants Phase 2 Phase 3 positive prefusion pregnant primary immunogenicity progression proportion Protein protocol provided pseudovirus neutralisation assay randomised Randomly reactogenicity receive Registered reported Research research and development responses robust Safety safety analysis safety endpoints safety profile Sanofi Pasteur SARS-CoV-2 second dose second vaccination selected Serious Adverse Event Serious Adverse Events serodiagnostic Seven severe COVID-19 Stratification study period supported systemic test result titre titres Treatment treatment group treatment groups Trial USA vaccination Vaccine was done were excluded were measured yes or no [DOI] 10.1016/S1473-3099(21)00764-7 PMC 바로가기 [Article Type] Clinical Trial
Comprehensive Oncogenic Features of Coronavirus Receptors in Glioblastoma Multiforme다형성 교모세포종에서 코로나바이러스 수용체의 포괄적인 발암성 특징Article Published on 2022-04-062022-09-12 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 진단, [키워드] ACE2 Analysis ANPEP approaches association bioinformatics Brain brain tissue Cancer caused clinical development Comprehensive coronavirus COVID-19 COVID-19 outbreak COVID-19 pandemic Cox regression analysis demonstrated DPP4 ENPEP expression functional GBM health system immune infiltration incidence individuals Kaplan-Meier survival curve molecular monocyte mRNA oncogenic Patient performed poor prognosis positively correlated potential therapeutic target protein level protein-protein interaction receptor receptors SARS-CoV-2 SARS-COV-2 infection signaling pathway significantly increased survival TMPRSS2 [DOI] 10.3389/fimmu.2022.840785 PMC 바로가기 [Article Type] Article
Plasmodium vivax transmission-blocking vaccines: Progress, challenges and innovationResearch article Published on 2022-04-012022-10-05 Journal: Parasitology International [Category] 비임상, [키워드] accelerate clinical development clinical trial Controlled human malaria infection (CHMI) develop Efficacy effort humans implementation malaria measure morbidity morbidity and mortality P. falciparum phase Plasmodium falciparum Plasmodium vivax Progress reached reduced reduction Research Significant significantly tested Transmission-blocking vaccine (TBV) Vaccine Vaccine development Vaccines Wheat germ cell-free protein synthesis system (WGCFS) [DOI] 10.1016/j.parint.2021.102525 [Article Type] Research article
A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques두 개의 인간 중화 항체의 조합은 사이노몰구스 원숭이에서 SARS-CoV-2 감염을 예방합니다Article Published on 2022-03-112022-09-11 Journal: Med (New York, N.Y.) [Category] COVID19(2023년), MERS, SARS, 변종, 비임상, 진단, [키워드] aerosol antibody Antibody therapeutics Antibody titer characterized clinical development Combination Concentration COVID-19 cynomolgus macaque cynomolgus macaques DARPA defined dose-dependent manner Efficacy Epitopes Fc region Fc-mediated effector function Future Human Human monoclonal antibody human serum in vitro insight Interaction intramuscular intramuscular route intravenous mAb mAbs monoclonal monoclonal antibody Mutation neutralized Neutralizing Neutralizing antibodies neutralizing antibody Neutralizing antibody titer NHP NHPs NIH non-human primate non-overlapping epitope non-overlapping epitopes office passive transfer persistence Prevent Prize Program Prophylactic prophylactically Prophylaxis Protective Receptor binding domain receptors reduce required Research respiratory respiratory tract SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike protein SARS-CoV-2 variant SARS-CoV-2 variants Science serum Spike protein Support supported technology therapy transferred Treatment Viral viral neutralization Virological [DOI] 10.1016/j.medj.2022.01.004 PMC 바로가기 [Article Type] Article
The development of broad-spectrum antiviral medical countermeasures to treat viral hemorrhagic fevers caused by natural or weaponized virus infectionsReview Published on 2022-03-082022-10-28 Journal: PLoS Neglected Tropical Diseases [Category] COVID-19, [키워드] acute viral infection animal animal challenge studies anticipated Antiviral antiviral activity approval approved Biological breadth caused CFR Chemical clinical clinical benefit clinical development clinical evaluation clinical study conducted coronavirus 2 COVID-19 development disease drug drugs targeting Ebola Ebola virus Ebola virus disease Efficacy effort enzyme Evidence examined example facilitated FDA feasible Fever filoviruses food GS-5734 Hemorrhagic high-consequence pathogen highlight Hospitalization humans include Infection infectious agents inhibitor Laboratory testing Level 4 mechanism medical countermeasure NHP NHPs numbers of patient office outbreak outcome pandemic pathogen pathway Patient performed Prevent Program randomized clinical trials randomized, controlled trial RCTs Regulatory regulatory pathway Remdesivir Research respiratory RNA virus RNA-dependent RNA polymerase robust rule Safe SARS-CoV-2 severe disease Support therapeutic therapy treat Treatment Trial Vaccine viral infection viral pathogen viral replication virus virus infection while [DOI] 10.1371/journal.pntd.0010220 PMC 바로가기 [Article Type] Review
The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studiesChAdOx1 벡터화 백신 AZD2816은 SARS-CoV-2 베타(B.1.351) 및 전임상 연구에서 우려되는 기타 변이체에 대해 강력한 면역원성을 유도합니다.Article Published on 2022-03-012022-09-11 Journal: EBioMedicine [Category] COVID19(2023년), SARS, 변종, [키워드] addition animals antibodies AstraZeneca AZD1222 B.1.351 B.1.617.2 Beta binding booster booster dose Booster vaccine booster vaccines caused ChAdOx1 ChAdOx1-vectored vaccine clinical development clinically Course death Delta dose effort expresse funds Gamma hospitalisation Immunity immunogenic increase in induce MRC mutated Mutation nCoV Neutralising Antibodies neutralising antibody new SARS-CoV-2 omicron other variant over P.1 pandemic preclinical study Proteins reduced regimens Research SARS CoV2 SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 virus single dose Spike protein Support T cell T cell response T cells the spike protein Vaccine Vaccines variants variants of concern vectored vaccine virus isolate was measured [DOI] 10.1016/j.ebiom.2022.103902 PMC 바로가기 [Article Type] Article